Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
- PMID: 33630669
- DOI: 10.1200/JCO.20.03215
Regarding the Addition of CDK4/6 Inhibitor to Postoperative Endocrine Therapy in Patients With HR-Positive HER2-Negative High-Risk Breast Cancer
Conflict of interest statement
Comment in
-
Reply to K. Hashimoto and A. Shimomura.J Clin Oncol. 2021 May 1;39(13):1507-1508. doi: 10.1200/JCO.20.03477. Epub 2021 Feb 25. J Clin Oncol. 2021. PMID: 33630658 No abstract available.
Comment on
-
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).J Clin Oncol. 2020 Dec 1;38(34):3987-3998. doi: 10.1200/JCO.20.02514. Epub 2020 Sep 20. J Clin Oncol. 2020. PMID: 32954927 Free PMC article. Clinical Trial.
Similar articles
-
Cyclin-dependent kinase 4 and 6 inhibitors in hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced breast cancer: a meta-analysis of randomized clinical trials.Breast Cancer Res Treat. 2020 Feb;180(1):21-32. doi: 10.1007/s10549-020-05528-2. Epub 2020 Jan 22. Breast Cancer Res Treat. 2020. PMID: 31970560 Review.
-
Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?Curr Oncol Rep. 2020 May 16;22(6):57. doi: 10.1007/s11912-020-00917-8. Curr Oncol Rep. 2020. PMID: 32415339 Review.
-
CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis.Lancet Oncol. 2020 Feb;21(2):250-260. doi: 10.1016/S1470-2045(19)30804-6. Epub 2019 Dec 16. Lancet Oncol. 2020. PMID: 31859246
-
Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.Cancer. 2020 Aug 1;126(15):3400-3416. doi: 10.1002/cncr.32931. Epub 2020 May 19. Cancer. 2020. PMID: 32426848 Review.
-
CDK4/6 inhibitor plus endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer: The new standard of care.Asia Pac J Clin Oncol. 2021 Jan;17 Suppl 1:3-14. doi: 10.1111/ajco.13555. Asia Pac J Clin Oncol. 2021. PMID: 33506626 Review.
Cited by
-
Role of abemaciclib in primary breast cancer: a narrative review of MonarchE.Transl Breast Cancer Res. 2022 Jan 31;3:3. doi: 10.21037/tbcr-21-27. eCollection 2022. Transl Breast Cancer Res. 2022. PMID: 38751527 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous